DEST On Other Exchanges

destiny pharma plc (DEST) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DESTINY PHARMA PLC (DEST)

Related News

No related news articles were found.

destiny pharma plc (DEST) Related Businessweek News

No Related Businessweek News Found

destiny pharma plc (DEST) Details

Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections. The company has collaboration agreement with China Medical System Holdings Limited; and research collaboration with the University of Southampton for targeting infections in diabetic foot ulcers and cystic fibrosis. The company was incorporated in 1996 and is headquartered in Brighton, the United Kingdom.

Founded in 1996

destiny pharma plc (DEST) Top Compensated Officers

CEO & Director
Total Annual Compensation: 232.9K GBP
Founder, Chief Scientific Officer & Director
Total Annual Compensation: 198.6K GBP
CFO, Company Secretary & Director
Total Annual Compensation: 117.1K GBP
Compensation as of Fiscal Year 2018.
destiny pharma plc
Destiny Pharma plc, Annual General Meeting, Jun 04, 2019

Destiny Pharma plc, Annual General Meeting, Jun 04, 2019, at 09:00 Coordinated Universal Time. Location: 60 New Broad Street London United Kingdom

Destiny Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2018

Destiny Pharma plc announced earnings results for the full year ended December 31, 2018. For the full year, the company announced operating loss was GBP 6.083 million compared to GBP 3.221 million a year ago. Net loss was GBP 5.166 million compared to GBP 2.977 million a year ago. Basic loss per share was GBP 0.119 compared to GBP 0.084 a year ago.

Destiny Pharma Appoints MedPharm to Develop New Xf-Drug Formulations

Destiny Pharma announced that it has appointed MedPharm as its expert partner to develop new topical formulations of the company's novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). The XF platform has already delivered a Phase 2 ready candidate, XF-73 nasal gel, for the prevention of post-surgical infections, that will begin Phase 2b testing in 2019. MedPharm will develop new formulations containing Destiny Pharma's XF-platform compounds for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections. MedPharm is a well-established, global leader in topical product development with a track record in developing a wide variety of formulations, from early concept stage through clinical development to full product approval.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

DEST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DEST.
View Industry Companies

Industry Analysis


Industry Average

Valuation DEST Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DESTINY PHARMA PLC, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at